Hamsters vaccinated with Ace-mep-7 DNA vaccine produced protective immunity against Ancylostoma ceylanicum infection

Wiśniewski, Marcin; Jaros, Sławomir; Bąska, Piotr; Cappello, Michael; Długosz, Ewa; Wędrychowicz, H.

doi:10.1016/j.exppara.2016.01.006

Cited by 14 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the immune response(s) is generally limited to T H 1, and particularly to CD8 + T C cells (Ferraro et al 2011 ). This may explain the weak antibody responses generated against r Acey -MEP-6 and r Acey -MEP-7 in golden hamsters using the pcDNA3·1+/Fugene 6 system against A. ceylanicum (Wisniewski et al 2013 , 2016 ), against r Ss -EAT-6 peptide in mice using the Lambda Uni-zap XR vector/ GM-CSF system against S. stercoralis (Kerepesi et al 2005 ), and against r Ts -NBLsp in mice using pcDNA3·1+ alone against T. spiralis . However, DNA vaccines in mice have proven to be highly efficacious against A. suum (Chen et al 2012 ) and T. spiralis (Yang et al 2010 a ; Pompa-Mera et al 2011 ; Wang et al 2016 ), with significant immunogenicity (albeit relatively weak for pcDNA3·1+/ Ts-NBLsp ) and protection achieved.…”

Section: Discussionmentioning

confidence: 99%

“…In a follow up study with an Acey-MEP-7 cDNA (paralog of Acey-MEP-6 ), single dose pcDNA3·1+/ Acey-MEP-7 /Fugene 6 (amount of plasmid was not reported) resulted in significantly lower A. ceylanicum worm burdens and FECs, and significantly higher post-challenge hematocrit compared with pcDNA3·1+/Fugene 6 control in golden hamsters ( Table 2 ) (Wisniewski et al 2016 ). Also, pcDNA3·1+/ Acey-MEP-7 /Fugene 6 resulted in significantly greater r Acey- MEP-7-specific total serum IgG responses (measured as optical density at 450 nm; OD450) compared with pcDNA3·1+/Fugene 6 control, although the difference was not great (average OD450 of ~0·7 compared with ~0·4) ( Table 2 ) (Wisniewski et al 2016 ). Although this study clearly indicates significant vaccine efficacy of pcDNA3·1+/ Acey-MEP-7 /Fugene 6, the issue with the empty vector/transfection reagent control also having an effect (Wisniewski et al 2013 ) has not been fully resolved, and immune correlates are weak.…”

Section: Recombinant Subunit Vaccines For Strongylidsmentioning

confidence: 99%

See 1 more Smart Citation

Recombinant subunit vaccines for soil-transmitted helminths

Noon

Aroian

2017

Parasitology

View full text Add to dashboard Cite

SUMMARYSoil-transmitted helminths (STHs) collectively infect one fourth of all human beings, and the majority of livestock in the developing world. These gastrointestinal nematodes are the most important parasites on earth with regard to their prevalence in humans and livestock. Current anthelmintic drugs are losing their efficacies due to increasing drug resistance, particularly in STHs of livestock and drug treatment is often followed by rapid reinfection due to failure of the immune system to develop a protective response. Vaccines against STHs offer what drugs cannot accomplish alone. Because such vaccines would have to be produced on such a large scale, and be cost effective, recombinant subunit vaccines that include a minimum number of proteins produced in relatively simple and inexpensive expression systems are required. Here, we summarize all of the previous studies pertaining to recombinant subunit vaccines for STHs of humans and livestock with the goal of both informing the public of just how critical these parasites are, and to help guide future developments. We also discuss several key areas of vaccine development, which we believe to be critical for developing more potent recombinant subunit vaccines with broad-spectrum protection.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Recombinant Subunit Vaccines For Strongylidsmentioning

confidence: 99%

Recombinant subunit vaccines for soil-transmitted helminths

Noon

Aroian

2017

Parasitology

View full text Add to dashboard Cite

show abstract

“…Both vaccines induced significant reductions in worm burden. Additionally, a 78% egg count reduction was observed in hamsters immunized with Ace-MEP-7 ( 62 ).…”

Section: Soil-transmitted Helminth Vaccines: Are We Getting Closer?mentioning

confidence: 98%

“…For example, the human immunodeficiency virus-1 (both as a prophylactic and an immunotherapeutic vaccine) ( 58 , 59 ), Zika virus ( 60 ), and Ebola virus vaccines ( 61 ) are currently in clinical trials. Comparatively, little progress has been made toward developing DNA vaccines against parasitic diseases, although several pre-clinical studies have shown promising results against hookworm infections ( 62 , 63 ), malaria ( 64 , 65 ), leishmaniasis ( 66 , 67 ), and schistosomiasis ( 68 , 69 ). Even though DNA vaccines offer several advantages when compared with recombinant vaccines, such as safety, improper protein folding and production cost, they have not been shown to be sufficient to induce a protective immune response ( 70 ).…”

Section: Prospects and Challenges For Anti-sths Vaccine Designmentioning

confidence: 99%

“…Promising results have also been achieved in hamsters immunized with DNA-based vaccines encoding the A. ceylanicum metalloprotease 6 (Ace-MEP-6) ( 63 ) or Ace-MEP-7 as an alternative strategy to recombinant protein production ( 62 ). Both vaccines induced significant reductions in worm burden.…”

Section: Soil-transmitted Helminth Vaccines: Are We Getting Closer?mentioning

confidence: 99%

See 1 more Smart Citation

Soil-Transmitted Helminth Vaccines: Are We Getting Closer?

Zawawi

Else

2020

Front. Immunol.

View full text Add to dashboard Cite

Parasitic helminths infect over one-fourth of the human population resulting in significant morbidity, and in some cases, death in endemic countries. Despite mass drug administration (MDA) to school-aged children and other control measures, helminth infections are spreading into new areas. Thus, there is a strong rationale for developing anthelminthic vaccines as cost-effective, long-term immunological control strategies, which, unlike MDA, are not haunted by the threat of emerging drug-resistant helminths nor limited by reinfection risk. Advances in vaccinology, immunology, and immunomics include the development of new tools that improve the safety, immunogenicity, and efficacy of vaccines; and some of these tools have been used in the development of helminth vaccines. The development of anthelminthic vaccines is fraught with difficulty. Multiple lifecycle stages exist each presenting stage-specific antigens. Further, helminth parasites are notorious for their ability to dampen down and regulate host immunity. One of the first significant challenges in developing any vaccine is identifying suitable candidate protective antigens. This review explores our current knowledge in lead antigen identification and reports on recent pre-clinical and clinical trials in the context of the soil-transmitted helminths Trichuris , the hookworms and Ascaris . Ultimately, a multivalent anthelminthic vaccine could become an essential tool for achieving the medium-to long-term goal of controlling, or even eliminating helminth infections.

show abstract